Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States.
about
Selective serotonin reuptake inhibitors for fibromyalgia syndromeClinical utility, safety, and efficacy of pregabalin in the treatment of fibromyalgiaPolypharmacy, Opioid Use, and Fibromyalgia: A Secondary Analysis of Clinical Trial Data."Fibromyalgia and quality of life: mapping the revised fibromyalgia impact questionnaire to the preference-based instruments".Severe forms of fibromyalgia with acute exacerbation of pain: costs, comorbidities, and length of stay in inpatient care.Cost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomized controlled trial.Identification of a potential fibromyalgia diagnosis using random forest modeling applied to electronic medical records.Evaluation of a self-management patient education program for patients with fibromyalgia syndrome: study protocol of a cluster randomized controlled trial.Describing the characteristics, treatment pathways, outcomes, and costs of people with persistent noncancer pain managed by community pain clinics and generating an indicative estimate of cost-effectiveness: feasibility study protocolChronic fatigue syndrome and fibromyalgia in Canada: prevalence and associations with six health status indicators.Fibromyalgia and Chronic Pain Syndromes: A White Paper Detailing Current Challenges in the Field.Evaluating increased resource use in fibromyalgia using electronic health records.Fibromyalgia comorbid with anxiety disorders and depression: combined medical and psychological treatment.Fibromyalgia: disease synopsis, medication cost effectiveness and economic burden.Predicting fibromyalgia, a narrative review: are we better than fools and children?A systematic review of the efficacy of venlafaxine for the treatment of fibromyalgia.Research design considerations for chronic pain prevention clinical trials: IMMPACT recommendations.Illness perceptions and burden of disease in fibromyalgia.Clinical Characteristics of Fibromyalgia in a Chronic Pain Population.Healthcare costs associated with elderly chronic pain patients in primary care.Classifying Fibromyalgia Syndrome as a Mental Disorder?-An Ambulatory Assessment Study.The management of fibromyalgia from a psychosomatic perspective: an overview.Socioeconomic value of intervention for chronic pain.The Economic Utility of Clinical Psychology in the Multidisciplinary Management of Pain.Is there evidence for any truly effective therapy in fibromyalgia?
P2860
Q24187263-F9BAD20A-676F-4BEB-A395-B198EB334C4BQ26764876-CC5BEA55-8607-4CF3-B1A3-416104C88404Q30276336-5AA45B59-4E09-4964-BD56-31040E870CE9Q33743545-0C35B837-C555-4600-80DC-9A4FFB46A635Q33766468-797A7AF4-EBD1-4ABE-BF6A-2A6683A7B32FQ34374726-5DDDF14F-0ABF-488A-A8F5-72C8B187ECA7Q35743484-71850DB2-67E1-43A0-9C8F-0C33F78737C1Q35914017-EBCCDE6B-A568-431A-95D0-F07F2CAB684DQ36926826-B2F1D19A-389D-4AFD-A3B3-4C4873439EE6Q37081339-4B59703E-7214-4584-9B59-72F76A0DBF21Q37152958-7574BEAA-D52F-4A5D-B5BA-E99C29251FE2Q37426947-5F485063-4AA6-4F14-810B-32755810D5D5Q38125645-AF24DE3D-A5B9-4894-9FCE-147299516C3BQ38185990-E5F4E6B2-520A-4F1F-B40B-769656C47864Q38195231-707BD36D-7059-490F-987C-E25B89D406A7Q38258054-94225FCF-4342-4EC6-BC5B-CB6D0278D3B1Q38426849-C88AA2FA-10D1-486A-90C9-EA5B74BF25F5Q38558687-DD1FEBCA-CD51-4C0A-AA6E-EA607FBE6A44Q38831991-359B2A2C-C1F2-4726-A686-4650323A6F19Q39003173-FE14EE42-0272-430B-9AA5-C2B76E74DDCEQ39273059-4C0AED35-E48A-4206-A701-9237AB1E80D1Q39417649-B697E5D7-6AEE-4A6D-8081-B8625FA42AF5Q39899117-0F54A61D-D541-4E53-B89C-872760844E6AQ45324994-99B4798C-B8A7-41F9-88CB-FFA8778EBB12Q54711248-0B4FEFB0-798D-4A57-B456-6A93D701AAED
P2860
Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Health-resource use and costs ...... ermany, and the United States.
@en
type
label
Health-resource use and costs ...... ermany, and the United States.
@en
prefLabel
Health-resource use and costs ...... ermany, and the United States.
@en
P2093
P2860
P356
P1476
Health-resource use and costs ...... ermany, and the United States.
@en
P2093
Andreas Winkelmann
Arthi Chandran
Caroline Schaefer
Gergana Zlateva
Serge Perrot
Tyler Knight
P2860
P304
P356
10.2147/CEOR.S41111
P407
P577
2013-04-23T00:00:00Z